Search / Trial NCT06617260

Longitudinal FolloW-up of Antimicrobial Resistance From Perinatal Acquisition (LWAPA): A SHARE Study ASSESSING AND PREVENTING Antimicrobial Resistance in the Perinatal Period

Launched by UNIVERSITY OF PENNSYLVANIA · Sep 25, 2024

Trial Information

Current as of October 03, 2024

Enrolling by invitation

Keywords

Antimicrobial

Description

The Longitudinal FolloW-up of Antimicrobial Resistance from Perinatal Acquisition (LWAPA) study will assess the extent of perinatally-acquired MDROs and GBS, exploring factors influencing both maternal and neonatal colonization and better understanding the long-term outcomes in families affected by MDRO colonization. By collecting samples at critical time points (e.g. during labour, after delivery, sequentially in the hospital, and then 3, 6, 9, and 12 months of age, the LWAPA study aims to identify modifiable factors influencing colonization risk. The results from this study can help info...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Pre-partum mothers will be eligible for recruitment if they have been admitted to the pre-partum ward (2F) at PMH. This includes mothers with:
  • * Pre-term labor (24-36 weeks gestation)
  • * Pre-eclampsia
  • * Post-dates (\>41 weeks gestation)-
  • Exclusion Criteria:
  • Mothers/babies who have been admitted for more than 96 hours will be excluded

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Gaborone, , Botswana

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0